New shot shows promise for weight loss in chinese men
NCT ID NCT07004322
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new medicine, NNC0519-0130, in 20 overweight or obese Chinese men. The goal was to see how the drug moves through the body and if it is safe. Participants received either the drug or a placebo for about 28 weeks. This is not a cure, but aims to help control weight and type 2 diabetes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Third Hospital, Northern Branch-Phase I
Beijing, Beijing Municipality, 100089, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?